Eplerenone for the treatment of cardiovascular disorders

Expert Rev Cardiovasc Ther. 2012 Jul;10(7):831-8. doi: 10.1586/erc.12.64.

Abstract

The clinical utility and ultimately guideline recommendations for aldosterone receptor-blocking agents in cardiovascular disorders is clearly mentioned by a number of major clinical outcome trials. This article reviews the pharmacology, clinical efficacy and safety of the two currently available receptor blocking agents: spironolactone and eplerenone. The potential utility of eplerenone and other mineralocorticoid receptor agents beyond current clinical indications will also be examined.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aldosterone / metabolism
  • Animals
  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / pharmacology
  • Cardiovascular Agents / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / metabolism
  • Eplerenone
  • Humans
  • Hydrocortisone / antagonists & inhibitors
  • Hydrocortisone / metabolism
  • Mineralocorticoid Receptor Antagonists / adverse effects
  • Mineralocorticoid Receptor Antagonists / pharmacology
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Receptors, Mineralocorticoid / metabolism
  • Spironolactone / adverse effects
  • Spironolactone / analogs & derivatives*
  • Spironolactone / pharmacology
  • Spironolactone / therapeutic use

Substances

  • Cardiovascular Agents
  • Mineralocorticoid Receptor Antagonists
  • Receptors, Mineralocorticoid
  • Spironolactone
  • Aldosterone
  • Eplerenone
  • Hydrocortisone